Research programme: antibacterials - Basilea Pharmaceutica

Drug Profile

Research programme: antibacterials - Basilea Pharmaceutica

Alternative Names: BAL 19764; BAL 29880; BAL0019764; BAL0029641; BAL0030205; BAL2057; BAL30376; HKI9924109

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Basilea Pharmaceutica
  • Class Macrolides; Monobactams
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Acne; Gram-negative infections; Gram-positive infections; Rosacea

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acne in Switzerland (Topical)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Gram-negative-infections in Germany (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Gram-negative-infections in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top